drugset
drugset / Trial / NCT06260553

Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC

NCT06260553 ↗

Phase 2 Unknown 40 enrolled Fujian Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy of metronomic chemotherapy combination with tislelizumab in EGFR/ALK-negative advanced NSCLC patients intolerant to first-line standard chemotherapy.

Timeline

Start
2024-02-07
Primary completion
2025-02-07
Completion
2025-08-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous
Subject Vinorelbine Small molecule 40 mg Oral

Indications

carcinoma